Mood Disorders in the News.

This section offers news briefs on U.S. Food and Drug Administration (FDA) decisions and issues associated with psychiatric treatments as of May 2024. The FDA has approved Rejoyn for the treatment of major depressive disorder (MDD) symptoms. Results of a study showed the effectiveness of lumateperon...

Descripción completa

Detalles Bibliográficos
Publicado en:Psychiatric Times Vol. 41; no. 5; pp. 7 - 9
Autor principal: Kuntz, Leah
Formato: Artículo
Publicado: MJH Life Sciences May2024
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=177095057&site=ehost-live
header:
  @attributes:
    shortDbName: ssf
    uiTerm: 177095057
    longDbName: Social Sciences Full Text (H.W. Wilson)
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        08932905
        8MJ
      jtl: Psychiatric Times
      issn: 08932905
      maglogo: N
    pubinfo:
      dt: May2024
      vid: 41
      iid: 5
      pid: 54670
      pub: MJH Life Sciences
    artinfo:
      ui: 177095057
      ppf: 7
      ppct: 2
      formats:
        fmt:
          @attributes:
            type: P
            size: 251KB
      tig:
        atl: Mood Disorders in the News.
      aug:
        au: Kuntz, Leah
      su:
        United States. Food & Drug Administration
        Psychotherapy
        Affective disorders
        Mobile apps
        Digital health
        Antipsychotic agents
        Antidepressants
      sug:
        subj:
          Psychotherapy
          Affective disorders
          United States. Food & Drug Administration
          Pharmaceutical and medicine manufacturing
          Medicinal and Botanical Manufacturing
          Mobile apps
          Digital health
          Antipsychotic agents
          Antidepressants
      ab: This section offers news briefs on U.S. Food and Drug Administration (FDA) decisions and issues associated with psychiatric treatments as of May 2024. The FDA has approved Rejoyn for the treatment of major depressive disorder (MDD) symptoms. Results of a study showed the effectiveness of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD. Another study showed the efficacy of BPL-003 benzoate salt formulation of mebudotenin for treatment-resistant depression.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: N
    holdings:
      @attributes:
        islocal: N